SMMT - Summit Therapeutics falls after late-stage data for lead asset
2024-05-24 07:45:37 ET
More on Akeso, Summit Therapeutics, etc.
- Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
- Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
- Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
- Summit spikes as Citi launches at Buy on lead asset
- Historical earnings data for Akeso, Inc.